Evidence map›Paper›PMID 40584348›Full record

ArticleACS omega2025

Engineered NIR-Responsive Exosomes for Synergistic Photoimmunotherapy of Hepatocellular Carcinoma.

Youbo Zhao, Yanan Li, Zhiwei He, Menghuan Li, Di Zhao, Chao Yu

Abstract read
In one paragraph

Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Youbo ZhaoDepartment of Hepatobiliary Surgery, The Affiliated Hospital of Guizhou Medical University, Center for Tissue Engineering and Stem Cell Research, Guizhou Medical University, No. 28 Guiyi Street, Yunyan District, Guiyang 550001, P. R. China.
Yanan LiCollege of Pharmaceutical Sciences, Soochow University, No. 199 Ren'ai Road, Industrial Park District, Suzhou 215123, P. R. China.
Zhiwei HeDepartment of Hepatobiliary Surgery, The Affiliated Hospital of Guizhou Medical University, Center for Tissue Engineering and Stem Cell Research, Guizhou Medical University, No. 28 Guiyi Street, Yunyan District, Guiyang 550001, P. R. China.
Menghuan LiSchool of Life Science, Chongqing University, No. 174 Shazheng Street, Shapingba District, Chongqing 400044, P. R. China.ORCID https://orcid.org/0000-0002-4558-7648
Di ZhaoSchool of Mechanical Engineering, Suzhou University of Science and Technology, No. 1 Kerui Road, High-Tech District, Suzhou 215009, P. R. China.
Chao YuDepartment of Hepatobiliary Surgery, The Affiliated Hospital of Guizhou Medical University, Center for Tissue Engineering and Stem Cell Research, Guizhou Medical University, No. 28 Guiyi Street, Yunyan District, Guiyang 550001, P. R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

T-cell immunotherapy holds tremendous promise for treating various types of cancer by boosting the infiltration and activity of T cells within tumor tissues. However, efficient recruitment of peripheral T cells to the tumor microenvironment (TME) remains a major clinical challenge. To address this limitation, here, we report an exosomal (EXO) immunotherapy for remodeling the immunosuppressive TME of hepatocellular carcinoma (HCC) into an immunosupportive state in a remotely controllable manner, for which the HCC-secreted exosomes are engineered with CXCL9 chemokine and cypate photothermal transducers (cypate@EXO-CXCL9). The engineered exosomes could efficiently home to the HCC site through homotypic targeting. Upon exposure to near-infrared light, the cypate-mediated photothermal effect readily induces immunogenic death of tumor cells while simultaneously disrupting the exosomes to release CXCL9. The released CXCL9 effectively attracts T cells to the tumor site and is subsequently activated by the HCC-derived antigens and damage associated molecular patterns to mount robust antitumor immunity. This study provides a facile strategy for the remodeling of the immunosuppressive HCC microenvironment, offering an approach for improving immunotherapeutic efficacy of solid tumors in the clinic.

Identifiers

PMID40584348
PMCPMC12199009

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.